Endocrine Abstracts

Tumor heterogeneity affects diagnosis, prognosis and response to therapy. Heterogeneity is found in both normal and neoplastic human mammary gland. For example, luminal estrogen receptor (ER)-negative cells can give rise to various phenotypes, including ER-negative and ER-positive mammary tumors, suggesting that the cell-of-origin does not necessarily reflect the tumor type. Regarding ER status, heterogeneity can challenge endocrine therapies; elimination of responsive clones ...

Kinases represent a main therapeutic targets in cancer treatment as their impairing is related to tumor growth and progression. Despite the increasing evidence that tumor microenvironment (TME) signaling influences the behavior of surrounding cancer epithelial cells, still little is known about what changes in stromal cells influence tumor cells’ behavior. TNBC patients are still lacking an effective therapy, as not much is known about the biology of this BC tumor subtype...

Introduction: The intricate interplay between fibroblasts and cancer cells significantly contributes to cancer invasion, extracellular matrix (ECM) modulation, and the development of drmg resistance. This study delves into understanding the specific influence of fibroblasts on Gastro-Intestinal neuroendocrine tumor (GI-NET) cell lines.Materials and Methods: Utilizing GOT1 and COLO320 cell lines, we incorporated Normal Human Dermal Fibroblasts (NF) in our...

Gastrointestinal neuroendocrine tumors (GI-NETs) present a challenging and diverse landscape, necessitating effective treatment strategies. Despite advancements, the demand for targeted therapies, particularly for advanced or metastatic cases, persists. Enhancing outcomes in GI-NETs management is crucial, emphasizing the need for ongoing research and development. In our laboratory, we conducted a multitarget compound screening, identifying FAK (BI-0319) and SYK (BI1002494) kin...

Introduction: Broncho-Pulmonary Neoplasms (BP-NENs) are rare neoplasms arising from neuroendocrine cells of the respiratory epithelium. Since previous studies in our lab have demonstrated the efficacy ofEverolimus, approved for BP-NENs treatment, and Dinaciclib, a Cyclins and CdKs inhibitor, on monolayer system we have investigated if a more complex tumour system could generate a change in drugs effects and cell resistance. Therefore, through the use of 3D culture model, we ha...

Introduction: LMTK3 is an oncogenic Receptor Tyrosine Kinase (RTK) implicated in resistance to endocrine therapy in breast cancer. Initially, LMTK3 was described as a regulator of Estrogen Receptor alpha (ERα) since it was found able to protect it from ubiquitin-mediated proteasomal degradation. In a cohort of breast cancer (BC) patients (n>600), LMTK3 protein levels and intronic polymorphisms were significantly associated with disease-free and overall surviv...

Background: Available medical treatments for Broncho-Pulmonary Neuroendocrine Neoplasm (BP-NENs) derived from clinical trials are not specific for the management of this malignancy. Sunitinib, a multi-receptor tyrosine-kinases (RTKs) inhibitor, mainly described as VEGFR inhibitor, has shown its efficacy in Pancreatic NENs but there are not available data about its action in BP-NENs. Our aim was to understand the effects of RTKs inhibition promoted by Sunitinib in order to eval...